-+ 0.00%
-+ 0.00%
-+ 0.00%

REPLIMUNE SHARES DOWN 32% AFTER FDA STAFF FLAGS BENEFIT CONCERNS ABOUT SKIN CANCER THERAPY

Reuters·07/28/2026 13:31:49

Please log in to view news